Related Experiment Video

Updated: Jan 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science

Rajeev Menon1, Emarjola Bako2, Shuhan Liu1

  • 1Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.

Clinical and Translational Science
|January 16, 2026
PubMed

Insights

Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate effective against platinum-resistant ovarian cancer (PROC) with high folate receptor alpha (FRα) expression. The MIRASOL trial demonstrated MIRV

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epithelial ovarian cancers (EOCs) frequently overexpress folate receptor alpha (FRα), making it an attractive target for therapy.
  • Platinum-resistant ovarian cancer (PROC) has limited treatment options and a poor prognosis, with median survival of 12-14 months.
  • Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting FRα, approved in 2022 for FRα-positive PROC.

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, pharmacodynamics, and clinical data of mirvetuximab soravtansine (MIRV).
  • To highlight the efficacy and safety of MIRV in patients with platinum-resistant ovarian cancer (PROC) and high FRα expression.

Main Methods:

  • Review of preclinical and clinical data for mirvetuximab soravtansine (MIRV).
  • Analysis of results from the Phase 3 MIRASOL trial comparing MIRV to chemotherapy in FRα-positive PROC.
  • Evaluation of objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Main Results:

  • MIRV demonstrated superior efficacy compared to chemotherapy in high FRα-expressing PROC.
  • MIRASOL trial showed MIRV achieved 42% ORR vs. 16% for chemotherapy, with median PFS of 5.6 vs. 4.0 months, and median OS of 16.5 vs. 12.8 months.
  • Key clinical efficacy and safety data for MIRV in PROC were reviewed.

Conclusions:

  • Mirvetuximab soravtansine (MIRV) offers a significant therapeutic advance for patients with FRα-positive platinum-resistant ovarian cancer (PROC).
  • The MIRASOL trial confirmed MIRV's superiority over standard chemotherapy, improving response rates and survival outcomes.
  • MIRV represents a crucial new option for a patient population with historically limited treatment choices.
Keywords:
antibody‐drug conjugatemechanism of actionmirvetuximab soravtansineovarian cancer

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

736
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
987